SOT 58th Annual Meeting and Tox Expo

Speak to our team of experts about your research and how our leading portfolio of hepatic products and research services can help you accelerate your R&D programs, gain regulatory approval, and achieve your commercial objectives. Visit BioIVT at booth # 3804.

Request a Meeting

Exhibitor Hosted Session

What is the Metformin Clinical DDI Study Design that Enables An Efficacy- and Safety-Based Dose Adjustment Decision?
March 12, 2019 | 12:00-1:00 PM
CC Room 339
Speaker: Dr. Maciej Zamek-Gliszcynski, GSK

Poster Session
March 11, 2019 | 9:15 am – 4: 30 pm
CC Exhibit Hall

P305Demonstration of Hepatocyte-Targeted siRNA Transfection and Gene Silencing in the Micro-Patterned Hepatocyte Co-Culture System (HEPATOPAC®)
Using a commercially-available, non-liposomal transfection reagent that targets hepatocytes we specifically delivered small-interfering RNAs (siRNA) into the hepatocytes in the HEPATOPAC® co-cultures.
Authors: Miranda Yang, Onyi Irrechukwu, and Jeannemarie Gaffney
Author Affiliation: BioIVT

We are proud to announce the launch of the XPRESSWAY® Profile Safety Package at SOT 2019.

Understanding the safety risks associated with drug targets is essential for understanding whether undesired side effects may derail a drug discovery & development program. Therefore, knowledge of where your target of interest is expressed across human tissue and organ systems supports both the validation of that target as relevant for a particular therapeutic approach and provides information as to where unexpected or undesired expression may be.

BioIVT’s XPRESSWAY® Profile Safety Package provides this data for 46 drug targets that are known to be associated with drug safety issues. For more information, click here.